{"id":"rifaximin","brandName":"Xifaxan","genericName":"rifaximin","companyId":"bausch","companyName":"Bausch Health","phase":"marketed","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Xifaxan, also known as rifaximin, is a non-absorbable, broad-spectrum antibiotic that inhibits bacterial DNA-directed RNA polymerase. It is used to treat various non-infectious gastrointestinal diseases, including irritable bowel syndrome, as indicated by its approval for conditions such as Diverticular Disease, Bloating, Functional Bowel Disorder, and Irritable Bowel Syndrome.","enrichmentLevel":3,"visitCount":0,"mechanism":{"target":"Nuclear receptor subfamily 1 group I member 2, Bacterial DNA-directed RNA polymerase","drugClass":"Rifamycin Antibacterial [EPC]"},"administration":{"route":"Oral"},"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"3983 reports"},{"date":"","signal":"HOSPITALISATION","source":"FDA FAERS","actionTaken":"1704 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"1193 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"1133 reports"},{"date":"","signal":"THERAPY INTERRUPTED","source":"FDA FAERS","actionTaken":"989 reports"},{"date":"","signal":"AMMONIA INCREASED","source":"FDA FAERS","actionTaken":"831 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"802 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"779 reports"},{"date":"","signal":"HEPATIC ENCEPHALOPATHY","source":"FDA FAERS","actionTaken":"762 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"713 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Peripheral edema","drugRate":"15%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"14%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"13%","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"12%","severity":"common","organSystem":""},{"effect":"Ascites","drugRate":"11%","severity":"common","organSystem":""},{"effect":"Muscle spasms","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Anemia","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Depression","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Nasopharyngitis","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Abdominal pain upper","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Dyspnea","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Pyrexia","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"5%","severity":"common","organSystem":""}],"contraindications":["Fever","Hemorrhagic diarrhea","Pseudomembranous enterocolitis"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Dysentery","drugRate":"","severity":"serious"},{"effect":"Taste loss","drugRate":"","severity":"serious"},{"effect":"Weight decrease","drugRate":"","severity":"serious"},{"effect":"Anorexia","drugRate":"","severity":"serious"},{"effect":"Nasal passage irritation","drugRate":"","severity":"serious"}]},"trials":["NCT03856359","NCT07185932","NCT01866826","NCT00269412","NCT04161053","NCT00743912","NCT03115697","NCT05677282","NCT07426705","NCT05587036","NCT01846663","NCT01842581","NCT06772064","NCT04674176","NCT02158182","NCT05621005","NCT01218568","NCT00364689","NCT05863364","NCT05071716","NCT02124512","NCT03719729","NCT01897051","NCT02738905","NCT02011841","NCT03613545","NCT00945334","NCT06328088","NCT00328380","NCT01542541","NCT04775329","NCT06718686","NCT06852274","NCT01769040","NCT04910815","NCT02342639","NCT01345175","NCT02884037","NCT06234046","NCT05297448","NCT02280044","NCT03420144","NCT06518850","NCT01137955","NCT06298409","NCT01904409","NCT02272868","NCT03958708","NCT04154735","NCT05604274"],"indications":{"approved":[{"name":"Diarrhea due to E. Coli","diseaseId":"diarrhea-due-to-e.-coli","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hepatic encephalopathy","diseaseId":"hepatic-encephalopathy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Irritable bowel syndrome with diarrhea","diseaseId":"irritable-bowel-syndrome-with-diarrhea","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":{"revenueYear":2024,"annualRevenue":1500,"revenueSource":"Verified: Bausch 10-K","revenueCurrency":"USD","revenueConfidence":"verified"},"patents":[{"type":"Method of Use","number":"7928115","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2029-07-24"},{"type":"Compound","number":"8193196","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2027-09-02"},{"type":"Method of Use","number":"8309569","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2029-07-18"},{"type":"Compound","number":"8741904","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2026-02-27"},{"type":"Method of Use","number":"8829017","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2029-07-24"},{"type":"Method of Use","number":"8642573","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2029-10-02"},{"type":"Method of Use","number":"9421195","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2029-07-24"},{"type":"Method of Use","number":"8969398","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2029-10-02"},{"type":"Method of Use","number":"8946252","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2029-07-24"},{"type":"Method of Use","number":"10335397","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2029-07-24"},{"type":"Method of Use","number":"10456384","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2029-02-26"},{"type":"Method of Use","number":"9629828","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2029-07-24"},{"type":"Method of Use","number":"10314828","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2029-07-24"},{"type":"Method of Use","number":"10703763","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2026-02-27"},{"type":"Method of Use","number":"10765667","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2029-02-26"},{"type":"Method of Use","number":"10709694","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2029-07-24"},{"type":"Method of Use","number":"11779571","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2029-02-26"},{"type":"Method of Use","number":"11564912","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2029-02-26"},{"type":"Formulation","number":"8518949","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2026-02-27"},{"type":"Formulation","number":"9271968","applicant":"SALIX PHARMACEUTICALS INC","territory":"US","tradeName":"XIFAXAN","expiryDate":"2026-02-27"}],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT03856359","phase":"Phase 2","title":"Pilot, Single Center, Open, Trial of Rifaximin in Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Duke University","isPivotal":false,"enrollment":10,"indication":"Alzheimer's Disease","completionDate":"2020-11-19"},{"nctId":"NCT07185932","phase":"EARLY/Phase 1","title":"Efficacy and Safety of Rifaximin in Treating Metabolic Associated Fatty Liver Disease: A Pilot Trial","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","isPivotal":false,"enrollment":40,"indication":"Metabolic-associated Fatty Liver Disease","completionDate":"2027-12-31"},{"nctId":"NCT01866826","phase":"Phase 1","title":"A Double Blind Randomized Placebo Controlled Study Examining the Effects of a Non-Absorbable (Rifaximin) Antibiotic on the Chronic Immune Activation Observed In HIV-infected Subjects","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":46,"indication":"HIV","completionDate":"2018-02-28"},{"nctId":"NCT00269412","phase":"Phase 2","title":"Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess The Efficacy and Safety of Three Different Doses (275, 550 AND 1100 MG) of Rifaximin Administered BID For Either Two or Four W","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","isPivotal":false,"enrollment":525,"indication":"Irritable Bowel Syndrome","completionDate":"2008-09"},{"nctId":"NCT04161053","phase":"Phase 3","title":"Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy","status":"RECRUITING","sponsor":"Tanta University","isPivotal":true,"enrollment":60,"indication":"Hepatic Encephalopathy","completionDate":"2028-12"},{"nctId":"NCT00743912","phase":"Phase 1","title":"A Phase 1, Single Arm, Open-Label Study to Evaluate the Effect of Rifaximin 550 MG Tablets TID on the Pharmacokinetics of Orally Administered Midazolam in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","isPivotal":false,"enrollment":24,"indication":"Pharmacokinetic","completionDate":"2008-11"},{"nctId":"NCT03115697","phase":"NA","title":"High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit-A Randomized Controlled Trial","status":"WITHDRAWN","sponsor":"Institute of Liver and Biliary Sciences, India","isPivotal":false,"enrollment":0,"indication":"Refractory Hepatic Encephalopathy","completionDate":"2019-04-15"},{"nctId":"NCT05677282","phase":"Phase 4","title":"A Randomized Controlled Trial Evaluating Single-dose Rifaximin Versus Azithromycin With Loperamide Adjunct for Treatment of Acute Watery Diarrhea","status":"RECRUITING","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","isPivotal":false,"enrollment":150,"indication":"Diarrhoea;Acute, Diarrhea Travelers","completionDate":"2025-12"},{"nctId":"NCT07426705","phase":"Phase 4","title":"Effect of Enterococcus Faecium and Bacillus Subtilis-Containing Multispecies Probiotic Supplementation on the Therapeutic Efficacy of Rifaximin α in Patients With Small Intestinal Bacterial Overgrowth","status":"NOT_YET_RECRUITING","sponsor":"Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji","isPivotal":false,"enrollment":100,"indication":"Small Intestinal Bacterial Overgrowth Syndrome (SIBO), IBS","completionDate":"2027-07-15"},{"nctId":"NCT05587036","phase":"Phase 2","title":"A Randomized, Triple-blind, Placebo-controlled Study on the Effect of Rifaximin on Psychobiological Functions in Healthy Men","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","isPivotal":true,"enrollment":60,"indication":"Healthy Volunteers, Stress","completionDate":"2025-07"},{"nctId":"NCT01846663","phase":"Phase 4","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepati","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","isPivotal":false,"enrollment":6,"indication":"Hepatic Encephalopathy","completionDate":"2016-02-22"},{"nctId":"NCT01842581","phase":"Phase 4","title":"A Multicenter, Randomized, Open-Label, Active-Controlled, Trial to Evaluate the Safety and Efficacy of Rifaximin 550 mg With and Without Lactulose in Subjects With a History of Recurrent Overt Hepatic","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","isPivotal":false,"enrollment":222,"indication":"Hepatic Encephalopathy, Cirrhosis","completionDate":"2014-12-17"},{"nctId":"NCT06772064","phase":"NA","title":"Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating: An Exploratory Study.","status":"RECRUITING","sponsor":"Xiuli Zuo","isPivotal":false,"enrollment":115,"indication":"SIBO","completionDate":"2025-12-01"},{"nctId":"NCT04674176","phase":"Phase 4","title":"The Potential Weight Loss Benefits of Rifaximin in an Intermittent Fasting Diet","status":"UNKNOWN","sponsor":"Bayhealth Medical Center","isPivotal":false,"enrollment":30,"indication":"Weight Loss","completionDate":"2022-01-01"},{"nctId":"NCT02158182","phase":"Phase 4","title":"Comparison of Three Different Schemes:Lactulose, L-ornithine L-aspartate, or Rifaximin, Versus Placebo, as Primary Prophylaxis of the Development of Hepatic Encephalopathy After Acute Variceal Bleedin","status":"COMPLETED","sponsor":"Hospital General de Mexico","isPivotal":false,"enrollment":88,"indication":"Hepatic Encephalopathy","completionDate":"2016-06"},{"nctId":"NCT05621005","phase":"Phase 2","title":"Rifaximin Prophylaxis Against Recurrence of Spontaneous Bacterial Peritonitis and Occurrence of Hepatorenal Syndrome in Decompensated Cirrhotic Egyptian Patients","status":"COMPLETED","sponsor":"Samar Atef Sebaweh Mohammed","isPivotal":false,"enrollment":104,"indication":"Ascites Infection","completionDate":"2022-08-01"},{"nctId":"NCT01218568","phase":"NA","title":"Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","isPivotal":false,"enrollment":120,"indication":"Hepatic Encephalopathy","completionDate":"2012-10"},{"nctId":"NCT00364689","phase":"Phase 3","title":"RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial","status":"TERMINATED","sponsor":"University of Miami","isPivotal":true,"enrollment":13,"indication":"Hepatic Encephalopathy","completionDate":"2008-07"},{"nctId":"NCT05863364","phase":"NA","title":"Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis: a Multi-center Randomized Prospective Study","status":"UNKNOWN","sponsor":"Xin Zeng","isPivotal":false,"enrollment":150,"indication":"Decompensated Cirrhosis","completionDate":"2025-12-31"},{"nctId":"NCT05071716","phase":"Phase 3","title":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrho","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bausch Health Americas, Inc.","isPivotal":true,"enrollment":524,"indication":"Hepatic Encephalopathy","completionDate":"2025-09"},{"nctId":"NCT02124512","phase":"Phase 2","title":"Dietary Fat, Lipoprotein and Lipopolysaccharide: Role in Insulin Resistance","status":"COMPLETED","sponsor":"Philip Kern","isPivotal":false,"enrollment":12,"indication":"Obese, Insulin Resistance","completionDate":"2019-05-31"},{"nctId":"NCT03719729","phase":"Phase 2","title":"A Phase II Study of Rifaximin (Xifaxan) for Patients With Sickle Cell Disease (SCD)","status":"UNKNOWN","sponsor":"New York Medical College","isPivotal":false,"enrollment":20,"indication":"Sickle Cell Disease, Antibiotics","completionDate":"2020-07-22"},{"nctId":"NCT01897051","phase":"Phase 2","title":"Hemodynamic Response of Rifaximin and Non-selective β-blocker Combination Therapy Versus Non-selective β-blocker Monotherapy in Cirrhotic Patients With Esophageal Varices","status":"UNKNOWN","sponsor":"Yonsei University","isPivotal":true,"enrollment":140,"indication":"Liver Cirrhosis, Portal Hypertension","completionDate":"2017-06"},{"nctId":"NCT02738905","phase":"EARLY/Phase 1","title":"Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease","status":"WITHDRAWN","sponsor":"Jason Stubbs, MD","isPivotal":false,"enrollment":0,"indication":"End Stage Renal Disease","completionDate":"2019-02-26"},{"nctId":"NCT02011841","phase":"Phase 3","title":"Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients: A Prospective, Multicenter, Randomized, Open-label, Controlled Phase III Study","status":"WITHDRAWN","sponsor":"Seoul National University Hospital","isPivotal":true,"enrollment":0,"indication":"Spontaneous Bacterial Peritonitis","completionDate":"2015-12"},{"nctId":"NCT03613545","phase":"Phase 2","title":"Efficacy and Safety of Fecal Microbiota Transplantation for Irritable Bowel Syndrome","status":"RECRUITING","sponsor":"Guangzhou First People's Hospital","isPivotal":true,"enrollment":120,"indication":"Irritable Bowel Syndrome, Fecal Microbiota Transplantation","completionDate":"2030-12-31"},{"nctId":"NCT00945334","phase":"NA","title":"Double-blind, Placebo Controlled Trial Comparing Neomycin to Rifaximin Plus Neomycin in the Treatment of Methane Positive Subjects With Constipation-predominant Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"Mark Pimentel, MD","isPivotal":false,"enrollment":37,"indication":"Constipation-predominant Irritable Bowel Syndrome","completionDate":"2013-06"},{"nctId":"NCT06328088","phase":"N/A","title":"Effect of Vegetarian Versus Non Vegetarian Based Diet in the Recurrence of Hepatic Encephalopathy in Patients With Cirrhosis:An Open Label Study","status":"UNKNOWN","sponsor":"Sir Ganga Ram Hospital","isPivotal":false,"enrollment":40,"indication":"Hepatic Encephalopathy","completionDate":"2024-10-16"},{"nctId":"NCT00328380","phase":"Phase 3","title":"A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety of Rifaximin for the Prevention of Travelers' Diarrhea in Subjects Traveling Outside the United States","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","isPivotal":true,"enrollment":660,"indication":"Diarrhea","completionDate":"2008-09"},{"nctId":"NCT01542541","phase":"NA","title":"A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","isPivotal":false,"enrollment":68,"indication":"Intestinal FDG Uptake","completionDate":"2012-10"},{"nctId":"NCT04775329","phase":"Phase 2","title":"Primary Prophylaxis for Spontaneous Bacterial Peritonitis in Decompensated Chronic Liver Disease With Small Bowel Bacterial Overgrowth: A Randomised Trial","status":"TERMINATED","sponsor":"Changi General Hospital","isPivotal":true,"enrollment":2,"indication":"Decompensated Cirrhosis, Small Bowel Bacterial Overgrowth Syndrome","completionDate":"2023-01-01"},{"nctId":"NCT06718686","phase":"Phase 1","title":"Rifaximin in Dementia Trial (RIDE): Gut-Brain Modulation With Rifaximin SSD in Dementia","status":"RECRUITING","sponsor":"Jasmohan Bajaj","isPivotal":false,"enrollment":20,"indication":"Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease","completionDate":"2027-12-30"},{"nctId":"NCT06852274","phase":"NA","title":"Management of Symptomatic Uncomplicated Diverticular Disease (SUDD) of the Colon With Clostridium Butyricum CBM588® Versus Rifaximin: Results From a Real-World Retrospective Italian Study","status":"COMPLETED","sponsor":"Dr. Amjad Khan","isPivotal":false,"enrollment":70,"indication":"Diverticular Diseases, Gastro-Intestinal Disorder","completionDate":"2024-10-31"},{"nctId":"NCT01769040","phase":"Phase 4","title":"Intestinal Decontamination With Rifaximin. Effects on the Inflammatory and Circulatory State in Patients With Cirrhosis and Ascites - A Randomised Controlled Clinical Study","status":"COMPLETED","sponsor":"Copenhagen University Hospital, Hvidovre","isPivotal":false,"enrollment":54,"indication":"Liver Cirrhosis, Ascites","completionDate":"2016-01"},{"nctId":"NCT04910815","phase":"NA","title":"Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting.","status":"UNKNOWN","sponsor":"Atmo Biosciences Pty Ltd","isPivotal":false,"enrollment":150,"indication":"Small Intestinal Bacterial Overgrowth","completionDate":"2024-08-01"},{"nctId":"NCT02342639","phase":"Phase 4","title":"Impact of Rifaximin Therapy on Intestinal Byproducts in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Jason Stubbs, MD","isPivotal":false,"enrollment":38,"indication":"Chronic Kidney Disease","completionDate":"2019-03-01"},{"nctId":"NCT01345175","phase":"Phase 3","title":"Randomized Control Trial Comparing Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","isPivotal":true,"enrollment":69,"indication":"Rectal Cancer","completionDate":"2023-03-23"},{"nctId":"NCT02884037","phase":"N/A","title":"Could Rifaximin Modify the Pathogenesis of NAFLD? AMulticenter, Randomized, Double-Blind, Placebo-Controlled Trial","status":"COMPLETED","sponsor":"Mansoura University","isPivotal":false,"enrollment":50,"indication":"Non-alcoholic Fatty Liver Disease","completionDate":"2016-10"},{"nctId":"NCT06234046","phase":"Phase 3","title":"Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin","status":"COMPLETED","sponsor":"Ain Shams University","isPivotal":true,"enrollment":80,"indication":"Spontaneous Bacterial Peritonitis","completionDate":"2023-12-15"},{"nctId":"NCT05297448","phase":"Phase 3","title":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrho","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bausch Health Americas, Inc.","isPivotal":true,"enrollment":466,"indication":"Hepatic Encephalopathy","completionDate":"2026-01"},{"nctId":"NCT02280044","phase":"Phase 2","title":"Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","isPivotal":true,"enrollment":30,"indication":"Dysentery, Diarrhea","completionDate":"2016-08-09"},{"nctId":"NCT03420144","phase":"Phase 2","title":"Growth Hormone Therapy and Its Effect on Nitrogen Metabolism and Malnutrition in Liver Cirrhosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","isPivotal":true,"enrollment":76,"indication":"Cirrhosis, Liver","completionDate":"2020-06-30"},{"nctId":"NCT06518850","phase":"Phase 1","title":"A Multicentre Study of Clinical Features and Efficacy of Small Intestinal Bacterial Overgrowth in Abdominal Distension Patients","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","isPivotal":false,"enrollment":30,"indication":"Small Intestine Bacterial Overgrowth","completionDate":"2025-12-31"},{"nctId":"NCT01137955","phase":"NA","title":"Double-blind Randomized Controlled Trial of Rifaximin for Persistent Symptoms in Patients With Celiac Disease","status":"COMPLETED","sponsor":"Columbia University","isPivotal":false,"enrollment":50,"indication":"Celiac Disease","completionDate":"2008-04"},{"nctId":"NCT06298409","phase":"Phase 1","title":"Evaluating the Effect of Rifaximin on the Regional Composition of the Gut Microbiota and Metabolic Profiles of Subjects With SIBO Using the CapScan® Collection Capsule","status":"RECRUITING","sponsor":"Envivo Bio Inc","isPivotal":false,"enrollment":34,"indication":"Small Intestinal Bacterial Overgrowth","completionDate":"2026-02-28"},{"nctId":"NCT01904409","phase":"Phase 2","title":"A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complication","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","isPivotal":false,"enrollment":420,"indication":"Liver Cirrhosis","completionDate":"2015-07"},{"nctId":"NCT02272868","phase":"Phase 1","title":"Fecal Microbial Transplant in Pediatric Crohn's Disease: A Double Blind Placebo Control Study","status":"TERMINATED","sponsor":"Seattle Children's Hospital","isPivotal":false,"enrollment":7,"indication":"Crohn's Disease","completionDate":"2016-10-01"},{"nctId":"NCT03958708","phase":"Phase 1","title":"Modulation of Gut Microbiota by Rifaximin in PD Patients","status":"UNKNOWN","sponsor":"Taipei Medical University Shuang Ho Hospital","isPivotal":false,"enrollment":20,"indication":"Parkinson Disease, Inflammation","completionDate":"2020-12-01"},{"nctId":"NCT04154735","phase":"Phase 2","title":"Autologous Hematopoietic Stem Cell Transplant for Crohn's Disease","status":"WITHDRAWN","sponsor":"Northwestern University","isPivotal":false,"enrollment":0,"indication":"Crohn's Disease","completionDate":"2024-03"},{"nctId":"NCT05604274","phase":"N/A","title":"Longitudinal Monitoring of Stool Characteristics","status":"COMPLETED","sponsor":"Hunter Holmes Mcguire Veteran Affairs Medical Center","isPivotal":false,"enrollment":60,"indication":"Cirrhosis, Liver","completionDate":"2023-10-28"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-10-15T00:00:00.000Z","mah":"SALIX PHARMS","brand_name_local":null,"application_number":"NDA021361"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"10703763","territory":"US","patent_type":"Method of Use","expiry_date":"2026-02-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9271968","territory":"US","patent_type":"Formulation","expiry_date":"2026-02-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8741904","territory":"US","patent_type":"Compound","expiry_date":"2026-02-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8518949","territory":"US","patent_type":"Formulation","expiry_date":"2026-02-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8193196","territory":"US","patent_type":"Compound","expiry_date":"2027-09-02T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10456384","territory":"US","patent_type":"Method of Use","expiry_date":"2029-02-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10765667","territory":"US","patent_type":"Method of Use","expiry_date":"2029-02-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11779571","territory":"US","patent_type":"Method of Use","expiry_date":"2029-02-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11564912","territory":"US","patent_type":"Method of Use","expiry_date":"2029-02-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8309569","territory":"US","patent_type":"Method of Use","expiry_date":"2029-07-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7928115","territory":"US","patent_type":"Method of Use","expiry_date":"2029-07-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9629828","territory":"US","patent_type":"Method of Use","expiry_date":"2029-07-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10314828","territory":"US","patent_type":"Method of Use","expiry_date":"2029-07-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8946252","territory":"US","patent_type":"Method of Use","expiry_date":"2029-07-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9421195","territory":"US","patent_type":"Method of Use","expiry_date":"2029-07-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10335397","territory":"US","patent_type":"Method of Use","expiry_date":"2029-07-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10709694","territory":"US","patent_type":"Method of Use","expiry_date":"2029-07-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8829017","territory":"US","patent_type":"Method of Use","expiry_date":"2029-07-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8642573","territory":"US","patent_type":"Method of Use","expiry_date":"2029-10-02T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8969398","territory":"US","patent_type":"Method of Use","expiry_date":"2029-10-02T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":17,"withResults":2},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=rifaximin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:19:24.063418+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T01:19:24.063332+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:19:30.415029+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:19:23.186877+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=rifaximin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:19:30.847235+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:19:21.770502+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:19:21.770531+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:19:21.770537+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:19:32.343735+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bacterial DNA-directed RNA polymerase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:19:31.901556+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1617/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:19:31.562481+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA021361","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:19:21.770541+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:19:36.100506+00:00","fieldsConflicting":0,"overallConfidence":0.95},"crossReferences":{"chemblId":"CHEMBL1617"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}